Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01591473 · ClinicalTrials.gov registry record · Phase 1
Safety Study of FluMist With and Without Ampligen
A Phase 1 study, sponsored by AIM ImmunoTech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01591473: Clinical Trial Phase 1 study, sponsored by AIM ImmunoTech.
NCT01591473 is a Phase 1 study that was terminated before completion, run by AIM ImmunoTech. The registered enrollment target is 55 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01591473, a Phase 1 study, was terminated before completion, sponsored by AIM ImmunoTech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate FluMist with and without Ampligen in healthy volunteers.
Primary Outcome
Reactogenicity; other adverse events, serious adverse events, new onset of chronic illnesses, and adverse events of special interest
Interventions
- DRUG Placebo
- DRUG Poly I:Poly C12U 50 ug
- DRUG Poly I:Poly C12U 200 ug
- DRUG Poly I:Poly C12U 500 ug
- DRUG Poly I:Poly C12U 1250 ug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Why NCT01591473 stopped before completion
NCT01591473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01591473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01591473 about?
NCT01591473 is a clinical study titled "Safety Study of FluMist With and Without Ampligen". The purpose of this study is to evaluate FluMist with and without Ampligen in healthy volunteers.
What is the current status of trial NCT01591473?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2012-04. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01591473?
The interventions under investigation include: Placebo (DRUG), Poly I:Poly C12U 50 ug (DRUG), Poly I:Poly C12U 200 ug (DRUG), Poly I:Poly C12U 500 ug (DRUG), Poly I:Poly C12U 1250 ug (DRUG).
Who is sponsoring clinical trial NCT01591473?
This trial is sponsored by AIM ImmunoTech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01591473's enrollment target sits among peer trials
55 918th of 2000 higher than 1,070 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia